Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EVT 201

Other · developed by Evotec Neurosciences GmbH

Phase 2 Most advanced trial (none active)
EVO Developer
1 Registered trials

What is EVT 201?

EVT 201 is an investigational drug studied in Sleep Initiation and Maintenance Disorders.

At a glance

Drug type
Other
Therapy area
Neurology, Psychiatry
Developer
Evotec Neurosciences GmbH (EVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
6J8AF7CLE4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00380003 Phase 2 Sleep Initiation and Maintenance Disorders Completed EVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Sleep Initiation and Maintenance Disorders

More from Evotec Neurosciences GmbH

Follow EVO, the company behind EVT 201

See EVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.